As filed with the U.S. Securities and Exchange Commission on April 26, 2023

 

Registration No. 333-

  

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

 

FORM F-6

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

For Depositary Shares Evidenced by American Depositary Receipts

___________________

 

ASLAN Pharmaceuticals Limited

(Exact name of issuer of deposited securities as specified in its charter)

 

N/A

(Translation of issuer's name into English)

 

The Cayman Islands

(Jurisdiction of incorporation or organization of issuer)

 

JPMORGAN CHASE BANK, N.A.

(Exact name of depositary as specified in its charter)

 

383 Madison Avenue, Floor 11

New York, New York 10179

Telephone: (800) 990-1135

(Address, including zip code, and telephone number, including area code, of depositary's principal executive offices)

____________________

 

Cogency Global Inc.

122 East 42nd Street, 18th Floor
New York, New York 10168

Telephone: (212) 947-7200

(Address, including zip code, and telephone number, including area code, of agent for service)

 

Copy to:

 

JPMorgan Chase Bank, N.A.

383 Madison Avenue, Floor 11

New York, New York 10179

Telephone: (800) 990-1135

 

It is proposed that this filing become effective under Rule 466

  ☒

immediately upon filing

  
  ☐  on (Date) at (Time)

  

 

If a separate registration statement has been filed to register the deposited shares, check the following box. ☐

 

CALCULATION OF REGISTRATION FEE

 

Title of each class of

Securities to be registered

 

Amount

to be registered

 

 Proposed maximum aggregate price per unit (1)

Proposed maximum

aggregate offering price (2) 

Amount of

registration fee

 

American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing twenty-five ordinary shares of ASLAN Pharmaceuticals Limited 100,000,000 $0.05 $5,000,000 $551
(1)Each unit represents one American Depositary Share.

(2)Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of American Depositary Receipts evidencing American Depositary Shares.

  

 

 

 

PART I

INFORMATION REQUIRED IN PROSPECTUS

 

The Prospectus consists of the proposed form of American Depositary Receipt (“ADR” or “American Depositary Receipt”) filed as Exhibit (a)(3) to this Registration Statement on Form F-6, which is incorporated herein by reference.

 

CROSS REFERENCE SHEET

 

Item 1. DESCRIPTION OF SECURITIES TO BE REGISTERED

 

Item Number and Caption

   Location in Form of American Depositary Receipt Filed Herewith as Prospectus
       
(1)    Name and address of Depositary   Introductory paragraph and bottom of face of American Depositary Receipt
       
(2)    Title of American Depositary Receipts and identity of deposited securities   Face of American Depositary Receipt, top center
       
Terms of Deposit:    
       
  (i)  Amount of deposited securities represented by one unit of American Depositary Shares   Face of American Depositary Receipt, upper right corner
       
  (ii)   Procedure for voting, if any, the deposited securities   Paragraphs (6), (11) and (12)
       
  (iii)   Collection and distribution of dividends   Paragraphs (4), (5), (7) and (10)
       
  (iv)  Transmission of notices, reports and proxy soliciting material   Paragraphs (3), (8), (11) and (12)
       
  (v)    Sale or exercise of rights   Paragraphs (4), (5) and (10)
       
  (vi)  Deposit or sale of securities resulting from dividends, splits or plans of reorganization   Paragraphs (3), (4), (5), (10) and (13)
       
  (vii)    Amendment, extension or termination of the Deposit Agreement   Paragraphs (15), (16) and (17)
       
  (viii)  Rights of holders of ADRs to inspect the transfer books of the Depositary and the list of Holders of ADRs   Paragraph (3)
       
  (ix)  Restrictions upon the right to deposit or withdraw the underlying securities   Paragraphs (1), (2), (4), (5) and (6)
       
  (x)    Limitation upon the liability of the Depositary   Paragraph (14)
       
(3)    Fees and Charges   Paragraph (7)

 

 

 

 

Item 2. AVAILABLE INFORMATION
     

Item Number and Caption

   Location in Form of American Depositary Receipt Filed Herewith as Prospectus
(a) Statement that ASLAN Pharmaceuticals Limited is subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, and, accordingly files certain reports with the Securities and Exchange Commission, and that such reports can be inspected and copied through the Securities and Exchange Commission’s EDGAR system or at public reference facilities maintained by the Securities and Exchange Commission in Washington, D.C.   Paragraph (8)

 

 

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 3. EXHIBITS

 

  (a)(1)

Form of Deposit Agreement. Form of Amended and Restated Deposit Agreement among ASLAN Pharmaceuticals Limited, JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners from time to time of ADRs issued thereunder. Previously filed as Exhibit (a) to Form F-6 (333-248632) filed with the Securities and Exchange Commission, which is incorporated herein by reference.

 

  (a)(2)

Form of Amendment No. 1 to Deposit Agreement. Form of Amendment No. 1 to the Amended and Restated Deposit Agreement among ASLAN Pharmaceuticals Limited, the Depositary and all Holders and Beneficial Owners from time to time of ADRs issued thereunder. Previously filed as Exhibit (a)(2) to the Post Effective Amendment No. 2 to Form F-6 (333-224273) filed with the Securities and Exchange Commission, which is incorporated herein by reference.

 

  (a)(3)  Form of American Depositary Receipt.  Filed herewith as Exhibit (a)(3).

 

  (b) Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. Not Applicable.

 

  (c) Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. Not Applicable.
     
  (d) Opinion of Ziegler, Ziegler & Associates LLP, counsel to the Depositary, as to the legality of the securities being registered. Filed herewith as Exhibit (d).
     
  (e) Certification under Rule 466. Filed herewith as Exhibit (e).
     
  (f) Power of Attorney for certain officers and directors of the Registrant. Included as part of the signature pages hereto.
     
Item 4. UNDERTAKINGS
   
  (a) The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the American Depositary Receipts, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.
     
  (b) If the amounts of fees charged are not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an American Depositary Receipt thirty days before any change in the fee schedule.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Act of 1933, as amended, JPMorgan Chase Bank, N.A. on behalf of the legal entity created by the Deposit Agreement, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in The City of New York, State of New York, on April 26, 2023.

 

  Legal entity created by the form of Deposit Agreement for the issuance of ADRs evidencing American Depositary Shares
     
  By:

JPMORGAN CHASE BANK, N.A., as Depositary

     
  By: /s/ Gregory A. Levendis
    Name: Gregory A. Levendis
    Title: Executive Director

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, ASLAN Pharmaceuticals Limited certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in Singapore, on April 26, 2023.

 

  ASLAN Pharmaceuticals Limited
     
  By: /s/ Carl Firth, Ph.D.
  Name: Carl Firth, Ph.D.
  Title: Chief Executive Officer

 

Each person whose signature appears below constitutes and appoints each of Carl Firth, Ph.D., Kiran Asarpota and Ben Goodger as attorneys-in-fact with full power of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933, as amended (the “Securities Act”), and any rules, regulations and requirements of the Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act of American depositary shares representing ordinary shares of the registrant (the “ADSs”), including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission with respect to such ADSs, to any and all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such Registration Statement; and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof.

 

Under the requirements of the Securities Act, this Registration Statement has been signed by the following persons on April 26, 2023, in the capacities indicated.

 

SIGNATURES

 

Signature

  

Title

 

/s/ Carl Firth, Ph.D.

Carl Firth, Ph.D.

  

Chief Executive Officer and Director

(principal executive officer)

 

/s/ Kiran Asarpota

Kiran Asarpota

  

Chief Operating Officer

(principal financial and accounting officer)

     

/s/ Andrew Howden

Andrew Howden

  

Chairman

 

 

/s/ Kathleen M. Metters, Ph.D.

Kathleen M. Metters, Ph.D.

   Director
   

/s/ Neil Graham, MBBS, M.D., MPH

Neil Graham, MBBS, M.D., MPH

  

Director

 

 

/s/ Robert E. Hoffman

Robert E. Hoffman

   Director

 

 

 

 

SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

 

Pursuant to the requirements of the United States Securities Act of 1933, as amended, the undersigned, the registrant’s duly authorized representative in the United States has signed this Registration Statement on Form F-6 on April 26, 2023.

 

  Authorized U.S. Representative
   
 

ASLAN Pharmaceuticals (USA) Inc., a Delaware corporation

     
  By:

/s/ Carl Firth, Ph.D.

  Name: Carl Firth, Ph.D.
  Title: Chief Executive Officer

 

 

 

 

INDEX TO EXHIBITS

 

Exhibit Number    
     
(a)(3)   Form of American Depositary Receipt
     

(d)    

  

Opinion of Counsel to the Depositary

     
(e)       Rule 466 Certification

 

ASLAN Pharmaceuticals (NASDAQ:ASLN)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos ASLAN Pharmaceuticals.